Eledon Pharma FY25 Net Loss Widens; Tegoprubart Phase 3 Development On Track In Kidney Transplant

Eledon Pharmaceuticals reported a wider full-year 2025 net loss and provided fourth-quarter operational updates, while outlining expected near-term clinical milestones. As a clinical-stage biotech with no commercial revenue, the larger loss highlights ongoing cash burn and will likely weigh on the stock absent financing or positive trial data. The company’s upcoming milestones are binary catalysts that could materially re-rate the equity if outcomes are favorable.

Analysis

Eledon Pharmaceuticals reported a wider full-year 2025 net loss and provided fourth-quarter operational updates, while outlining expected near-term clinical milestones. As a clinical-stage biotech with no commercial revenue, the larger loss highlights ongoing cash burn and will likely weigh on the stock absent financing or positive trial data. The company’s upcoming milestones are binary catalysts that could materially re-rate the equity if outcomes are favorable.